Clinical CareCommunicable DiseaseHealth EducationResearch/Evidence-Based

HEPLISAV-B

Dynavax Technologies Corporation

HEPLISAV-B, the only 2-dose in 1 month hepatitis B virus (HBV) vaccine, represents a significant innovation in adult vaccination. It is believed to activate TLR9, stimulating the innate immune response. HEPLISAV-B is the only 2-dose HBV vaccine available for adults and is unanimously recommended by the ACIP (Advisory Committee on Immunization Practices).






Request Information





 
By requesting information, you agree to share the email you provided at the time of registration with the exhibitor for follow-up. Click on “Submit” to share your email or “Cancel” to cancel your information request.
 
 
Comments